FTFabiola Traina

Fabiola Traina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fabiola Traina has a total of 641 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Allogeneic Hematopoietic Cell Transplantation for Pediatric Unstable Hemoglobinopathies: An Aggregated Cohort with Long-Term Follow-Up from a Brazilian Center

    by Annie Karoline Feijó Costa, Joana Teresa Bisinella de Faria, Gabriela Ventura de Almeida Silva, Renata Fittipaldi da Costa Guimarães, Carlos Eduardo Setanni Grecco, Thalita Cristina de Mello Costa, Fabíola Traina, Belinda Pinto Simões, Luiz Guilherme Darrigo

    Background/Objectives: Severe unstable hemoglobinopathies may cause transfusion dependence from early childhood, and allogeneic hematopoietic cell transplantation (allo-HCT) is the only established curative option. Pediatric experience with allo-HCT for unstable hemoglobinopathies is limited to isolated reports, and long-term outcomes remain poorly characterized. The objective of this study was to characterize the clinical and molecular features, transplant approaches, and long-term outcomes of two Brazilian patients with unstable hemoglobinopathies, in the context of the published pediatric literature. Methods: We performed a retrospective analysis of two children with unstable hemoglobinopathies who underwent allo-HCT at a Brazilian center. PubMed/MEDLINE and Scopus were searched for pediatric cases published between 2002 and 2025 using terms related to unstable hemoglobin variants and hematopoietic transplantation. Published cases were combined with the Brazilian patients to form an aggregated cohort. Clinical, molecular, transplant, and follow-up data were analyzed descriptively. Results: The aggregated cohort included 13 patients and 15 allo-HCT procedures, using matched sibling, haploidentical, and other alternative donors. All patients were transfusion-dependent before transplantation. Two patients required retransplantation after graft failure. At last follow-up, the nine published patients with available outcome data and both Brazilian patients were alive and transfusion independent. The Brazilian patients maintained complete donor chimerism and transfusion independence for 8 and 9 years, the longest follow-up reported in this population. One remained transfusion independent after retransplantation for secondary graft failure. Conclusions: Allo-HCT may achieve durable transfusion independence in children with severe unstable hemoglobinopathies, but the small number of reported cases limits the interpretation of these findings. Our series adds long-term follow-up data supporting this approach and highlights the need for larger, prospective studies to guide donor selection and conditioning strategies in this rare population.

  • Open Access

    The murine Irs1 knockout model, generated by the spontaneous Irs1S57X mutation in homozygosity, exhibits high embryonic lethality, limiting studies of adult hematopoiesis

    by Bruna Alves Fenerich, Jaqueline Cristina Fernandes, Cleide Lúcia Araújo Silva, João Agostinho Machado-Neto, Fabiola Traina

  • Open Access

    Autophagy inhibition potentiates the antileukemic effect of FLT3 inhibitors and overcomes resistance in FLT3-ITD acute myeloid leukemia

    by Manuela Albuquerque de Melo, Brunno Gilberto Santos de Macedo, Diego A. Pereira-Martins, Antônio Bruno Alves-Silva, Natasha Peixoto Fonseca, Livia Bassani Lins de Miranda, Cleide Lucia Araújo Silva, Priscila Santos Scheucher, Jan Jacob Schuringa, João Agostinho Machado-Neto, et al.

    Autophagy induction has recently emerged as a mechanism of resistance to FLT3 inhibitors (FLT3i) in patients with FLT3 -ITD mutant acute myeloid leukemia (AML). Here, we assessed the molecular mechanisms of autophagy inhibition associated with FLT3i and its impact on cell survival and pharmacological resistance. In FLT3 -ITD AML cell lines (MOLM13 and MV4-11), treatment with first- and second-generation FLT3i (midostaurin and quizartinib, respectively) induced autophagy. Combining FLT3i with autophagy inhibitors further decreased cell viability and increased cell apoptosis in both cell lines and in primary patient samples. Label-free quantification proteomics of MOLM13 cells revealed that RFC4 (Replication Factor C Subunit 4), an autophagy regulator linked to increased chemosensitivity, and GATD3/C21orf33 (Glutamine Amidotransferase Class 1 Domain Containing 3) proteins were upregulated only in the combined group, while 11 proteins mostly associated with chemoresistance were downregulated. In vivo, the combination of midostaurin and autophagy inhibition improved overall survival in MOLM13-transplanted mice. ATG5 - (Autophagy Related 5) and ATG7 -knockdown (Autophagy Related 7) increased sensitivity to first- and second-generation FLT3i in MOLM13 cells. To investigate the potential of autophagy inhibition in overcoming FLT3i resistance, we generated MV4-11 cells resistant to quizartinib (MV4-11QR). The resistant cell line exhibited higher basal levels of autophagy compared to the parental cell line. The combination of quizartinib and chloroquine demonstrated a synergistic effect in MV4-11QR cells and this effect was associated with greater inhibition of the FLT3 receptor compared to the monotherapies. Therefore, combining FLT3i with autophagy inhibition enhances the FLT3i antileukemic efficacy and overcomes pharmacological resistance.


  • Open Access

    Comparison of nutritional risk index and body mass index in predicting survival outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective study

    by Bruna Silvestre Françoso, Isabela Laurêncio Schiavoni, Thauany Nantes Guirao, Barbara David dos Santos, Thalita Cristina de Mello Costa, Anderson Marliere Navarro, Fabiola Traina, Juliana Maria Faccioli Sicchieri


  • Top Cited Papers
    Open Access

    High mtDNA content identifies oxidative phosphorylation-driven acute myeloid leukemias and represents a therapeutic vulnerability

    by Diego A. Pereira-Martins, Isabel Weinhäuser, Emmanuel Griessinger, Juan L. Coelho-Silva, Douglas R. Silveira, Dominique Sternadt, Ayşegül Erdem, Bruno Kosa L. Duarte, Prodromos Chatzikyriakou, Lynn Quek, et al.

    Metabolic reprogramming is a hallmark of cancer, with acute myeloid leukemia (AML) being no exception. Mitochondrial function, particularly its role in protecting tumor cells against chemotherapy, is of significant interest in AML chemoresistance. In this study, we identified mitochondrial DNA content (mtDNAc), measured by quantitative PCR, as a simple and precise marker to stratify the metabolic states of AML patients. We show that patients with high mtDNAc are associated with increased mitochondrial metabolism and a higher dependency on oxidative phosphorylation (OXPHOS), often correlating with chemoresistance. Clinically, patients receiving cytarabine and an anthracycline-based regimen (7 + 3 regimen) experienced inferior relapse-free survival and a higher overall rate of leukemia recurrence. Ex vivo experiments using primary AML samples confirmed cytarabine resistance in high mtDNAc patients, which could be overcome by inhibiting mitochondrial complex I. The FDA-approved drug metformin, which targets mitochondrial metabolism, significantly enhanced apoptosis in response to chemotherapy or targeted agents, such as venetoclax, in AML models. However, metformin-treated cells adapted by increasing glycolysis and NAD+ production, a resistance mechanism that could be bypassed by targeting the nicotinamide phosphoribosyltransferase (NAMPT) enzyme. In summary, we demonstrated that mtDNAc is an effective tool for assessing the metabolic state of AML cells. This method can be easily implemented in clinical practice to identify chemoresistant patients and guide personalized treatment strategies, including novel combination therapies for those with a high reliance on mitochondrial metabolism.


  • The NLRP3 inflammasome and its role in acute myeloid leukemia onset and development

    by Brunno Gilberto Santos de Macedo, Manuela Albuquerque de Melo, Diego Antonio Pereira-Martins, João Agostinho Machado-Neto, Fabiola Traina

  • Open Access

    A common ground: an in silico assessment of the sources of intrinsic ex vivo resistance to venetoclax in acute myeloid leukemia

    by Brunno Gilberto Santos de Macedo, Manuela Albuquerque de Melo, Diego Antonio Pereira-Martins, João Agostinho Machado-Neto, Fabiola Traina


  • An updated outlook on autophagy mechanism and how it supports acute myeloid leukemia maintenance

    by Brunno Gilberto Santos de Macedo, Manuela Albuquerque de Melo, Diego Antonio Pereira-Martins, João Agostinho Machado-Neto, Fabiola Traina


  • External validation and calibration of the HoLISTIC Consortium's advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the Brazilian Hodgkin lymphoma registry

    by Valeria Buccheri, Frederico Rafael Moreira, Irene Biasoli, Nelson Castro, Carolina Colaço Villarim, Fabiola Traina, Talita Silveira, Monica Kopschitz Praxedes, Cristiana Solza, Leila Perobelli, et al.

    Summary: The Hodgkin lymphoma International Study for Individual Care (HoLISTIC) Consortium's A‐HIPI model, developed in 2022 for advanced‐stage classical Hodgkin lymphoma (cHL), predicts survival within 5 years amongst newly diagnosed patients. This study validates its performance in the Brazilian Hodgkin lymphoma registry. By 2022, the Brazilian HL registry included 1357 cHL patients, with a median 5‐year follow‐up. Probabilities for 5‐year progression‐free survival (PFS) and overall survival (OS) were calculated using A‐HIPI‐model equations. Discrimination (Harrell C‐statistic/Uno C‐statistic) and calibration measures assessed external validation and calibration. Lab values beyond the allowed range were excluded, mirroring the initial A‐HIPI analysis. A total of 694 advanced‐stage cHL patients met the original inclusion criteria (age 18–65 years, Stage IIB‐IV). Median age was 31 years; 46.3% were females. Stage distribution was IIB (33.1%), III (27.4%), IV (39.5%). Bulky disease in 32.6%. Five‐year PFS and OS were 68.4% and 86.0%, respectively. Harrell C‐statistics were 0.60 for PFS and 0.69 for OS, and Uno C‐statistics were 0.63 for PFS and 0.72 for OS. Calibration plots demonstrated well‐calibrated predictions with calibration slopes of 0.91 and 1.03 for 5‐year OS and PFS, respectively. Despite differing patient, clinical characteristics, and socioeconomic factors, the baseline prediction tool performed well in the Brazilian cohort, demonstrating adequate discrimination and calibration. This supports its reliability in diverse settings.


  • Open Access

    Autophagy and inflammasome activation are associated with poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemia

    by Brunno Gilberto Santos de Macedo, Manuela Albuquerque de Melo, Diego Antonio Pereira-Martins, João Agostinho Machado-Neto, Fabíola Traina

    Beyond its clinical diversity and severity, acute myeloid leukemia (AML) is known for its complex molecular background and for rewiring biological processes to aid disease onset and maintenance. FLT3 mutations are among the most recurring molecular entities that cooperatively drive AML, and their inhibition is a critical molecularly oriented therapeutic strategy. Despite being a promising avenue, it still faces challenges such as intrinsic and acquired drug resistance, which led us to investigate whether and how autophagy and inflammasome interact and whether this interaction could be leveraged to enhance FLT3 inhibition as a therapeutic strategy. We observed a strong and positive correlation between the expression of key genes associated with autophagy and the inflammasome. Gene set enrichment analysis of the FLT3-ITD samples and their ex vivo response to five different FLT3 inhibitors revealed a common molecular signature compatible with autophagy and inflammasome activation across all poor responders. Inflammasome activation was also shown to strongly increase the likelihood of a poor ex vivo response to the FLT3 inhibitors quizartinib and sorafenib. These findings reveal a distinct molecular pattern within FLT3-ITD AML samples that underscores the necessity for further exploration into how approaching these supportive parallel yet altered pathways could improve therapeutic strategies.